ATE551069T1 - Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung - Google Patents

Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung

Info

Publication number
ATE551069T1
ATE551069T1 AT03725536T AT03725536T ATE551069T1 AT E551069 T1 ATE551069 T1 AT E551069T1 AT 03725536 T AT03725536 T AT 03725536T AT 03725536 T AT03725536 T AT 03725536T AT E551069 T1 ATE551069 T1 AT E551069T1
Authority
AT
Austria
Prior art keywords
compositions
fusion polypeptide
polypeptide vaccines
mucin fusion
mucin
Prior art date
Application number
AT03725536T
Other languages
English (en)
Inventor
Jan Holgersson
Original Assignee
Recopharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recopharma Ab filed Critical Recopharma Ab
Application granted granted Critical
Publication of ATE551069T1 publication Critical patent/ATE551069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03725536T 2002-04-22 2003-04-22 Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung ATE551069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37509502P 2002-04-22 2002-04-22
PCT/IB2003/002207 WO2003088995A2 (en) 2002-04-22 2003-04-22 Mucin fusion polypeptide vaccines, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE551069T1 true ATE551069T1 (de) 2012-04-15

Family

ID=29251230

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725536T ATE551069T1 (de) 2002-04-22 2003-04-22 Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung

Country Status (8)

Country Link
US (2) US8034351B2 (de)
EP (1) EP1517700B1 (de)
JP (1) JP2005530493A (de)
AT (1) ATE551069T1 (de)
AU (1) AU2003228067B2 (de)
CA (1) CA2483473A1 (de)
ES (1) ES2385032T3 (de)
WO (1) WO2003088995A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4276432B2 (ja) 2000-12-22 2009-06-10 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｍｕｃ１による細胞増殖調節方法
EP1517923A2 (de) * 2002-04-22 2005-03-30 Recopharma AB Zusammensetzungen und verfahren zur inhibierung der mikrobiellen adhesion
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
JP4549666B2 (ja) * 2003-12-12 2010-09-22 タカラバイオ株式会社 抗体の製造方法
US7807636B1 (en) 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
AU2006209246A1 (en) 2005-01-28 2006-08-03 Biomodifying Llc Anti-MUC1 alpha/beta antibodies
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
WO2007087420A2 (en) * 2006-01-23 2007-08-02 Recopharma Ab Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
EP2264061A1 (de) * 2006-01-26 2010-12-22 Recopharma AB Zusammensetzung und verfahren zur Bekämpfung von viralen Infektionen
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2008118487A2 (en) 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines
WO2009136298A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
MX2010013059A (es) * 2008-05-30 2010-12-20 Glycofi Inc Cepa de levadura para la produccion de proteinas con galactosa alfa-1,3-enlazada terminal.
JP2014501748A (ja) * 2010-12-21 2014-01-23 リコファーマ アーベー 涙代用物
SI3401402T1 (sl) 2012-06-08 2021-03-31 Alkermes Pharma Ireland Limited Ligandi modificirani s krožno permutacijo kot agonisti in antagonisti
CN104800838B (zh) * 2015-04-14 2018-01-09 深圳市中联生物科技开发有限公司 MUC1‑Fc多肽疫苗及其制备方法和应用
JP6441167B2 (ja) * 2015-05-15 2018-12-19 愛三工業株式会社 蒸発燃料処理装置
EP3666888A4 (de) 2017-08-10 2021-09-01 Good T Cells, Inc. Verfahren zur aktivierung von t-zellen zur krebsbehandlung
EP4314073A4 (de) 2021-03-24 2025-02-19 Alkermes, Inc. Upar-antikörper und fusionsproteine damit

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4710761A (en) 1985-07-09 1987-12-01 American Telephone And Telegraph Company, At&T Bell Laboratories Window border generation in a bitmapped graphics workstation
EP0454781B1 (de) 1989-01-23 1998-12-16 Chiron Corporation Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ATE123065T1 (de) * 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd Proteine und deren herstellung.
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
EP0754057B1 (de) 1994-03-15 2000-06-28 Medical College Of Pennsylvania And Hahnemann University Alpha-galactosyl-epitope enthaltende zusammensetzungen und verfahren für impfstoffe
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
EP1007569B1 (de) * 1997-02-11 2009-04-08 Immunomedics, Inc. Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
SE9701127D0 (sv) 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes

Also Published As

Publication number Publication date
US8034351B2 (en) 2011-10-11
US20120034220A1 (en) 2012-02-09
WO2003088995A3 (en) 2004-06-03
US20040002585A1 (en) 2004-01-01
AU2003228067B2 (en) 2008-05-29
ES2385032T3 (es) 2012-07-17
EP1517700B1 (de) 2012-03-28
AU2003228067A1 (en) 2003-11-03
CA2483473A1 (en) 2003-10-30
EP1517700A2 (de) 2005-03-30
WO2003088995A2 (en) 2003-10-30
JP2005530493A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
FR20C1016I1 (de)
DK1584685T3 (da) Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
CY1119106T1 (el) Αντισωματα εναντι masp-2
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
DK1185691T3 (da) Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EP1594536A4 (de) Adjuvante influenza-vakzine
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
DK1259547T3 (da) Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
UA85536C2 (en) Viral antigens
DK1530637T3 (da) Carlsberg-subtilisin-proteiner med nedsat immunogenitet
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
EP1565080A4 (de) Neue immunogene proteine von leptospira
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2003093298A3 (en) Immunogenic peptides
DK1444356T3 (da) Identifikation af epitoper og mindskelse af allergeniciteten af fødevareproteiner
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
ATE285250T1 (de) Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien
DE60324816D1 (de) Impfstoffe gegen allergien
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form